
AI and retinal maps reveal disease associations
Study finds retinal thinning associated with many systemic disorders, including MS, diabetes and dementia

Study finds retinal thinning associated with many systemic disorders, including MS, diabetes and dementia

A cross-sectional study found patients diagnosed with allergic conjunctivitis have little knowledge of the condition, indicating a need for targeted education to improve attitudes and practices, poten

Driven by a desire to improve eyelid health and comfort for patients who wear makeup and suffer from dry eye, optometrist and CCLS NZ president Adele Jefferies has created Elin Eyes, a locally made or

Auckland team to investigate vitamin D levels in patients with HLA-B27-associated uveitis

A Greek study has identified Macrophomina phaseolina, a fungal pathogen primarily affecting plants, as a rare but emerging cause of endophthalmitis in humans.

Long-term New Zealand Orthoptic Society Inc (NZOSI) executive Sally-Anne Herring is the society’s new president, replacing Nia Stonex.

‘Oriel’, the NHS’s first digitally enabled ‘smart’ hospital is due to open in 2027 as the new home for Moorfields Eye Hospital NHS Foundation Trust and the University College London (UCL) Institute of Ophthalmology.

Funding provided to map children’s eye health data to improve kids’ eyecare in Aotearoa

US researchers found higher long-term variability and mean levels of blood pressure (BP) were associated with faster visual field (VF) progression in patients with glaucoma. Published in JAMA

US researchers have recommended clinicians monitor orthokeratology (ortho-k) patients' refraction, tomography, pachymetry and corneal biomechanics until stability is achieved before considering refrac

Apellis Pharmaceuticals announced Australia’s Therapeutic Goods Administration (TGA) has approved Syfovre (pegcetacoplan intravitreal injection) for the every-other-month treatment of adults with geog

Ashvattha Therapeutics has secured additional financing up to US$50 million (NZ$88.4m) for its at-home monthly subcutaneously-administered treatment for neovascular age-related macular degeneration (n
